Clinical

Dataset Information

0

A phase III, randomized, controlled study of mFOLFOX6 + bevacizumab combination therapy versus mFOLFOX6 + panitumumab combination therapy in chemotherapy-naive patients with KRAS/NRAS wild-type, incurable/unresectable, advanced/recurrent colorectal cancer


ABSTRACT: Interventions: mFOLFOX6 + panitumumab mFOLFOX6 + bevacizumab Primary outcome(s): 1. Overall survival (OS) 2. OS for Participants with Left-sided Tumors Study Design: Parallel Randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2632097 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2019-11-25 | PXD012283 | Pride
2019-11-25 | PXD012304 | Pride
2021-11-15 | GSE188711 | GEO
| 2658055 | ecrin-mdr-crc
| 97976 | ecrin-mdr-crc
| 2611228 | ecrin-mdr-crc
2024-06-10 | GSE176499 | GEO
| 97964 | ecrin-mdr-crc
| 2632102 | ecrin-mdr-crc
| 2614086 | ecrin-mdr-crc